Beating drug tests and defending positive results: A toxicologist's perspective

Beating Drug Tests and Defending Positive Results: A Toxicologist's Perspective

Volumn , Issue , 2010, Pages 1-152

  Dasgupta, Amitava ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900606001     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60761-527-9     Document Type: Book

References (320)

1. McGinnis JM, Foege WH. Mortality and morbidity attributable to use of addictive substances in the United States. Proc Assoc Am Physicians 1999; 111:109-118
2. US Department of Health and Human Services: National survey on drug use and health, Washington DC. US Department of Health and Human Services; 2006 (Office of Applied Studies)
3. Milkkelsen SL, Ash KO. Adulterants causing false negatives in illicit drug testing. Clin Chem 1988;34:2333-2336
4. Paul BD, Martin KK, Maguilo J, Smith ML. Effects of pyridinium chlorochromate adulterant (urine luck) on testing of drugs of abuse and a method for quantitative detection of chromium (VI) in urine. J Anal Toxicol 2000; 24:233-237
5. Dasgupta A, Wahed A, Wells A. Rapid spot tests for detecting the presence of adulterants in urine specimens submitted for drug testing. Am J Clin Pathol 2002; 117:325-329
6. ElSohly MA, Feng S, Kopycki WJ, Murphy TP, Jones AB, Davis A, Carr D. A procedure to overcome interferences caused by adulterant "Klear" in the GC-MS analysis of 11-nor-A9-THC-9-COOH. J Anal Toxicol 1997; 20:240-242
7. Tsai SC, ElSohly MA, Dubrovsky T, Twarowska B, Towt J, Salamone SJ. Determination of five abused drugs in nitrite-adulterated urine by immunoassay and gas chromatography-mass spectrometry. J Anal Toxicol 1998; 22:474-480
8. Tsai LS, ElSohly MA, Tsai SF, Murphy TO, Twarowska B, Salamone SJ. Investigation of nitrite adulteration on the immunoassay and GC-MS analysis of cannabinoids in urine specimens. J Anal Toxicol 2000; 24:708-714
9. Dasgupta A. The effect of adulterants and selected ingested compounds on drugs of abuse testing in urine. Am J Clin Pathol 2007; 228:491-503
10. Maresove V, Hampl J, Chundela Z, Zrcek F et al. The identification of a chlorinated MDMA. J Anal Toxicol 2005; 29:353-358
11. Bossong MG, Van Dijk JP, Niesink RJ. Methylone and mCPP, two new drugs of abuse. Addict Biol 2005; 10:321-323
12. Gillespie TJ, Gandolfi AUJ, Davis TP, Morano RA. Identification and quantification of alpha-methylfentanyl in post mortem specimens. J Anal Toxicol 1982; 6:139-142
13. Hibbs J, Perper J, Winek CL. An outbreak of designer drug-related deaths in Pennsylvania. JAMA 1991;265:1011-1013
14. Dyer JE. Gamma-hydroxybutyrate: a health food product producing coma and seizure like activity. Am J Emerg Med 1991; 9:321-324
15. Gamma-hydroxybutyrate. In: RC Baselt, RC Cravey. Disposition of Toxic Drugs and Chemicals in Man. Chemical Toxicology Institute, Foster City, CA, 1995, pp 348-349
16. Caldicott DG, Chow FY, Burns BJ, Felgate PD et al. Fatalities associated with the use of gamma-hydroxybutyrate and its analogs in Australia. Med J Aust 2004; 181:310-313
17. Kintz P, Villain M, Pelissier AL, Cirimele V et al. Unusually high concentrations in fatal GHB case. J Anal Toxicol 2005; 29:582-585
18. Kintz P, Cirimele V, Jamey C, Ludes B. Testing for GHB in hair by GC/MS after single exposure. Application to document sexual assault. J Forensic Sci 2003; 48:195-200
19. Lekskulchai V, Mokkhavesa C. Evaluation of Roche Abuscreen ONLINE amphetamine immunoassay for screening of new amphetamine analogues. J Anal Toxicol 2001; 25: 471-475
20. Staack RF, Fritschi G, Maurer HH. Studies on the metabolism and the toxicological analysis of the new piperazine-like designer drug N-benzylpiperazine (BZP, A2) using gas chromatography-mass spectrometry (GC-MS). J. Chromatogr. B Analyt Technol Biomed Life Sci 2002; 773:35-46
21. Elian AA. GC-MS determination of gamma-hydroxybutyric acid (GHB) in blood. Forensic Sci Int 2001; 122:43-47
22. de la Torre R, Farre M, Navarro M, Pacifici R et al. Clinical pharmacokinetics of amphetamine and related substances: monitoring in conventional and non conventional matrices. Clin Pharmacokinetic 2004; 43:157-185
23. Green CE, LaValley SE, Tyson CA. Comparison of amphetamine metabolism using isolated hepatocytes from five species including human. J Pharamacol Exp Ther 1986; 237: 931-936.
24. Maresove V, Hampl J, Chundela Z, Zrcek F et al. The identification of a chlorinated MDMA. J Anal Toxicol 2005; 29: 353-358.
25. Bossong MG, Van Dijk JP, Niesink RJ. Methylone and mCPP, two new drugs of abuse. Addict Biol 2005; 10: 321-323.
26. Theobald DS, Fehn S, Maurer HH. New designer drug 2, 5-dimethoxy- 4propylthio-β-phenylethylamine (2C-T-7): studies on its metabolism and toxicological determination in rat urine using gas chromatography/mass spectrometry. J Mass Spectrom 2005; 40: 105-116.
27. de la Torre R, Farre M, Roset PN, Pizarro N et al. Human pharmacology f MDMA: pharmacokinetics, metabolism and disposition. Ther Drug Monit 2004; 26: 137-144.
28. Carmo H, Brulport M, Hermes M, Oesch F et al. CYP2D6 increases toxicity of designer drug 4-methylthioamphetamine (4-MTA). Toxicology 2007; 229: 236-244.
29. Tominaga GT, Garcia G, Dzierba A, Wong J. Toll of methamphetamine on the trauma system. Arch Surg 2004; 139: 844-847.
30. Kojima T, Une I, Yashiki M, Noda J et al. A fatal methamphetamine poisoning associated with hyperpyrexia. Forensic Sci Int 1984; 24: 87-93.
31. Byard RW, Gilbert J, James R, Lokan RJ. Amphetamine derivative fatalities in South Australia-is "Ecstasy" the culprit? Am J Forensic Med Pathol 1998; 19: 261-265.
32. Nemeroff CB. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull 2003; 37: 133-146.
33. Freudenthal RI, Carroll FI. Metabolism of certain commonly used barbiturates. Drug Metab Rev 1973; 2: 265-278.
34. Romain N, Giroud C, Michaud K, Mangin P. Suicide by injection of a veterinarian barbiturate euthanasia agent: report of a case report and toxicological analysis. Forensic Sci Int 2003; 131: 103-107.
35. Brandt-Casadevall C, Krompecher T, Giroud C, Mangin P. A case of suicide disguised as natural death. Sci Justice 2003; 43: 41-143.
36. Tracqui A, Kintz P, Mangin P, Lugnier AA et al. A fatality involving secobarbital, nitrazepam and codeine. Am J Forensic Med Pathol 1989; 10: 130-133.
37. Wang JS, Devane CL. Pharmacokinetics and drug interactions of the sedative hypnotics. Psychopharmacol Bull 2003; 37: 10-29.
38. Greenblatt DJ, von Moltke LL, Harmatz JS, Ciraulo DA. Alprazolam pharmacokinetics: metabolism and plasma levels: clinical implications. J Clin Psychiatry 1993; 54(Suppl): 4-11.
39. Charlson F, Degenhardt L, McLaren J, Hall W et al. A systematic review of research examining benzodiazepine-related mortality. Pharmacoepidemiol Drug Saf 2009; 18: 93-103.
40. Carlsten A, Waern M, Holmgren P, Allebeck P. The role of benzodiazepines in elderly suicide. Scand J Public Health 2003; 31: 224-228.
41. Martello S, Oliva A, De Giorgio F, Chiarotti M. Acute flurazepam intoxication: a case report. Am J Forensic Med Pathol 2006; 27: 55-57.
42. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004; 74: 1317-1324.
43. Ramaekers JG, Berghaus G, van Laar M, Drummer OH. Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend 2004; 73: 109-119.
44. MacInnes DC, Miller KM. Fatal coronary artery thrombosis associated with cannabis smoking. J R Coll Gen Pract 1984; 34(267): 575-576.
45. Steketee JD. Cortical mechanism of cocaine sensitization. Crit Rev Neurobiol 2005; 17: 69-86.
46. Kolbrich EA, Barnes AJ, Gorelick DA, Boyd SJ. Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration
47. Peretti FJ, Isenschmid DS, Levine B, Caplan YH. Cocaine fatality: an unexplained blood concentration in a fatal overdose. Forensic Sci Int 1990; 48: 135-138.
48. Fineschi V, Centini F, Monciotti F, Turillazzi E. The cocaine "body staffer" syndrome: a fatal case. Forensic Sci Int 2002; 126: 7-10.
49. Andrews P. Cocaethylene toxicity. J Addict Dis 1997; 16: 75-84.
50. Kreek MJ, Bart G, Lilly C, LaForge KS et al. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 2005; 57: 1-26.
51. Brown P, Kraus C, Fleming M, Reddy S. Methadone: applied pharmacology and use as adjunctive treatment in chronic pain. Postgrad Med J 2004; 80: 654-659.
52. Laurenzana LM, Owens SM. Metabolism of phencyclidine by human liver microsomes. Drug Metab Dispos 1997; 25: 557-563.
53. Barkin EL, Barkin SJ, Barkin DS. Propoxyphene (dextropropoxyphene): a critical review of a weak analgesic that should remain in antiquity. Am J Ther 2006; 13: 534-542.
54. Ionescu-Pioggia M, Bird M, Orzack MH, Benes F et al. Methaqualone. Int Clin Psychophar-macol 1988; 3: 97-109.
55. McCarthy G, Myers B, Siegfried N. Treatment of methaqualone dependance in adults. Cochrane Database Syst Rev 2005; 18: CD004146.
56. Ricordel I, Wenzek M. Cannabis and safety work: evolution of its detection within the controls of narcotics since 2004 to the SNCF. Ann Pharm Fr 2008; 66: 255-260.
57. Roberts S, Fallon LF Jr. Administrative issues related to addiction in the workplace. Occup Med 2001; 16: 509-515.
58. Bush DM. The US mandatory guidelines for federal workplace drug testing programs: current status and future considerations. Forensic Sci Int 2008; 174: 111-119.
59. Dackis CA, Pottash AJC, Annitto W, Gold MS. Persistence of marijuana level after supervised abstinence. Am J Psychiatry 1982; 139: 1196-1198.
60. Huestis MA, Mitchell JM, Cone EJ. Detection time of marijuana metabolite in urine by immunoassays and GC-MS. J Anal Toxicol 1995; 19: 443-449.
61. Huestis MA, Darwin WD, Shimoura E, Lalani SA et al. Cocaine and metabolites urinary excretion after controlled smoke administration. J Anal Toxicol 2007; 31: 462-468.
62. Moeller KE, Lee KC, Kissack JC. Urine drug screen: practical guides for clinicians. Mayo Clin Proc 2008; 83: 66-76.
63. Loor R, Lingerfelter C, Wason PP, Tank K et al. Multiplex assay of amphetamine, metham-phetamine, and ecstasy drug using CEDIA technology. J Anal Toxicol 2002; 26: 267-273.
64. Lekskulchai V, Mokkhavesa C. Evaluation of Roche Abuscreen ONLINE amphetamine immunoassay for screening of new amphetamine analogs. J Anal Toxicol 2001; 25: 471-475.
65. McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manag 2005; 10(A): 15A-22A.
66. Fraser AD, Worth D. Urinary excretion of 11-nor-9-carboxy-delta9- tetrahydrocannaninol and 11-hydroxy-delta9-THC: cannabinoid metabolites to creatinine ratio stuffy IV. Forensic Sci Int 2004; 143: 147-152.
67. Goodwin RS, Darwin WD, Chiang CN, Shih M et al. Urinary elimination of 11-nor-9-cerboxy-delta 9-tetrahydrocannabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol 2008; 32: 562-569.
68. Joern WA. Detection of past and recurrent marijuana use by a modified GC/MS procedure. J Anal Toxicol 1987; 11: 49-52.
69. Cone EJ, Tsadik A, Oyler J, Darwin WD. Cocaine metabolism and urinary excretion after different routes of administration. Ther Drug Monit 1998; 20: 556-560.
70. Wu AH, Ostheimer D, Cremese M, Forte E et al. Characterization of drug interference caused by coelution of substances in gas chromatography/mass spectrometry confirmation of targeted drugs in full scan and selected ion monitoring modes. Clin Chem 1994; 40: 216-220.
71. Dasgupta A, Mahle C, McLemore J. Elimination of fluconazole interference in gas chromatography/mass spectrometric confirmation of benzoylecgonine, the major metabolite of cocaine using pentafluropropionyl derivative. J Foresnsic Sci 1996; 41: 511-513.
72. Jenkins AJ, Cone EJ. Pharmacokinetics: Drug absorption, distribution, and elimination. In: SB Karch ed. Drug Abuse Handbook. CRC Press, Washington, D.C., 1998, pp. 151-201.
73. Liu RH, McKeehan AM, Edwards C, Foster G et al. Improved gas chromatography/mass spectrometric analysis of barbiturates in urine using centrifuge-based solid phase extraction, methylation with d-5 pentobarbital as internal standard. J Forensic Sci 1994; 39: 1504-1514.
74. Klette KL. Urine benzodiazepine screening using Roche Online® KIMS immunoassay with glucuronidase hydrolysis and confirmation by gas chromatography-mass spectrometry. J Anal Toxicol 2005; 29: 193-200.
75. Wang PH, Liu C, Tsay WI et al. Improved screen and confirmation test of 7-aminoflunitrazepam in urine specimens for monitoring flunitrazepam (Rohypnol) in urine. J Anal Toxicol 2002; 26: 411-418.
76. Cheng PS, Lee CH, Liu C, Chen CS. Simultaneous determination of Ketamine, Tramadol, Methadone and their metabolites in urine by gas chromatography-mass spectrometry. J Anal Toxicol 2008; 32: 253-259.
77. McNally AJ, Pilcher I, Wu R, Salamone SJ et al. Evaluation of the online immunoassay for propoxyphene: comparison to EMIT II and GC-MS. J Anal Toxicol 1996; 20: 537-540.
78. Schneider S, Wennig R. Interference of diphenhydramine with the EMIT II immunoassay for propoxyphene. J Anal Toxicol 1999; 23: 637-638.
79. Brenner C, Hui R, Passarelli J, Wu R et al. Comparison of methaqualone excretion patterns using Abuscreen ONLINE and EMIT II immunoassay and GC/MS. Forensic Sci Int 1996; 79: 31-41.
80. Moore KA. Amphetamines/sympathomimetic amines. In: Levine B ed. Principles of Forensic Toxicology. AACC Press, Washington, D.C, 2003, pp. 341-348.
81. Grinstead GF. Ranitidine and high concentration phenylpropanolamine cross react in the EMIT monoclonal amphetamine/methamphetamine assay. Clin Chem 1989; 35: 1998-1999.
82. Joseph R, Dickerson S, Wills R, Frankenfield D et al. Interference by non-steroidal antiin-flammatory drugs in EMIT and TDX assays for drugs of abuse. J Anal Toxicol 1995; 19: 13-17.
83. Dietzen DJ, Ecos K, Friedman D, Beason S. Positive predictive values of abused drug immunoassay on the Beckman Synchron in a veteran population. J Anal Toxicol 2001; 25: 174-178.
84. Joseph R, Dickerson S, Willis R, Frankenfield D et al. Interference by nonsteroidal anti-inflammatory drugs in EMIT and TDx assays for drugs of abuse. J Anal Toxicol 1995; 19: 13-17.
85. Mayrovitz HN, Sims N. Biophysical effects of water and synthetic urine on skin. Adv Skin Wound Care 2001; 14: 302-308.
86. Cook JD, Strauss KA, Caplan YH, Lodico CP et al. Urine pH: the effects of time and temperature after collection. J Anal Toxicol 2007; 31: 486-496.
87. Co-owners of the whizzinator pled guilty to conspiring to defeat federal drug test. United States Attorney's office: Western District of Pennsylvania. http://www.usdoj.gov/usao/paw/pr/2008-november-2008-11-24-03.html Accessed 4/14/2009.
88. Dasgupta A. The effect of adulterants and selected ingested compounds on drugs of abuse testing in urine. Am J Clin Pathol 2007; 228: 491-503.
89. Finkel KW. Water intoxication presenting as a suspected contaminated urine sample for drug testing. South Med J 2004; 97: 611-613.
90. Gardner JW, Gutmann FD. Fatal water intoxication of an army trainee during urine drug testing. Mil Med 2002; 167: 435-437.
91. Klonoff DC, Jurow AH. Acute water intoxication as a complication of urine drug testing in the workplace. JAMA 1991; 265: 84-85.
92. George S, Braithwaite. RA. An investigation into the extent of possible dilution of specimens received for urinary drugs of abuse screening. Addiction 1995; 90: 967-970.
93. Fraser AD, Zamecnik J, Keravel J, McGrath L, Wells J. Experience with urine drug testing by the correctional service of Canada. Forensic Sci Int 2001; 121: 16-22.
94. Jaffee WB, Trucco E, Teter C, Levy S et al. Focus on alcohol and drug abuse: ensuring validity in urine drug testing. Psychiatr Serv 2008; 59: 140-142.
95. Needleman SD, Porvaznik M. Creatinine analysis in single collection urine specimens. J Forensic Sci 1992; 37: 1125-1133.
96. Edwards C, Fyfe MJ, Liu RH, Walia AS. Evaluation of urine specimen adulteration indicators. J Anal Toxicol 1993; 17: 251-252 [Letter to the editor].
97. Luceri F, Godi F, Messeri G. Reducing false negative tests in urinary drugs of abuse screening. J Anal Toxicol 1997; 21: 244-245 [Letter to the editor].
98. Fraser AD, Zamecnik J. Impact of lowering the screening and confirmation cutoff values for urine drug testing based on dilution indicators. Ther Drug Monit 2003; 25: 723-727.
99. Soldin SJ, Morales AJ, D'Angelo LJ, Bogema SC, Hicks JC. The importance of lowering the cut-off concentrations of urine screening and confirmatory tests for benzoylecgonine/cocaine [Abstract]. Clin Chem 1991; 37: 993.
100. Luzzi VI, Saunders AN, Koenig JW, Turk J, Lo SF, Garg U, Dietzen DJ. Analytical performance of immunoassays for drugs of abuse below established cutoff values. Clin Chem 2004; 50: 717-722.
101. NLCP. State of Science-Update #1. Subject: Urine specimen validity testing: evaluation of scientific data used to define a urine specimen as substituted (February 14, 2000). http://workplace.samhsa.gov/ResourceCenter/ resource.asp?RCategoryID=8$String+Regulations/Guidance
102. Cook JD, Caplan YH, LoDico CP, Bush DM. The characterization of human urine for specimen validity determination in workplace drug testing: a review. J Anal Toxicol 2000; 24: 579-588.
103. Edgell K, Caplan YH, Glass LR, Cook JD. The defined HHS/DOT substituted urine criteria validated through controlled hydration study. J Anal Toxicol 2002; 26: 419-423.
104. Barbanel CS, Winkelman JW, Fischer GA, King AJ. Confirmation of the department of transportation criteria for a substituted urine specimen. J Occup Environ Med 2002; 44: 407-416.
105. Cook JD, Hannon MW Sr, Vo T, Caplan YH. Evaluation of freezing point depression osmo-lality for classifying random urine specimens defined as substituted under HHS/DOT. J Anal Toxicol 2002; 26: 424-429.
106. MRO Case Studies (Health and Human Services of the US Government) 2005: (http://workplace.samhsa.gov/DrugTesting/Files-Drug-Testing/MROs/ MRO%20Case%20Studies %20-%20February%202005.pdf)
107. Cone EJ, Lange R, Darwin WD. In vivo adulteration: excess fluid ingestion cause false negative marijuana and cocaine urine test results. J Anal Toxicol 1998; 22: 460-473.
108. Coleman DE, Baselt RC. Efficacy of two commercial products for altering urine drug test results. J Toxicol Clin Toxicol 1997; 35: 637-642.
109. Deventer K, Delbeke FT, Roels K, Van Ecnoo P. Screening for 18 diuretics and probenecid in doping analysis by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2002; 16: 529-535.
110. Thorngren JO, Ostervall F, Garle M. A high performance throughput multicomponent screening method for diuretics, masked agents, central nervous system (CNS) stimulants and opiates in human urine by UPLC-Ms/Ms. J Mass Spectrom 2008; 43: 980-982.
111. Markowitz JS, Donovan JL, DeVance CL, Chavin KD. Common herbal supplements did not produce false positive results on urine drug screens analyzed by enzyme immunoassay. J Anal Toxcol 2004; 28: 272-273.
112. Winek CL, Elzein EO, Wahba WW, Feldman JA. Interference of herbal drinks with urinalysis for drugs of abuse. J Anal Toxicol 1993; 17: 246-247.
113. Floren AE, Fitter W. Contamination of urine with diazepam and mefenamic acid from an Oriental remedy. J Occup Med 1991; 33: 1168-1169.
114. Liu SY, Woo SO, Koh HL. HPLC and GC-MS screening of Chinese proprietary medicine for undeclared therapeutic substances. J Pharm Biomed Anal 2001; 24: 983-992.
115. Wagener RE, Linder MW, Valdes R Jr. Decreased signal in Emit assays of drugs of abuse in urine after ingestion of aspirin: potential for false-negative results. Clin Chem 1994; 40: 608-612.
116. Larsen J, Fogerson R. Nonsteroidal anti-inflammatory drugs interfere in TDx assays for abused drugs. Clin Chem 1988; 34: 987-988.
117. Rollins DE, Jennison TA, Jones G. Investigation of interference of nonsteroidal anti-inflammatory drugs in urine tests for abused drugs. Clin Chem 1990; 36: 602-606.
118. Zacher JL, Givone DM. False-positive urine opiate screening associated with fluoroquinolone use. Ann Pharmacother 2004; 38: 1525-1528.
119. Marchei E, Pellegrini M, Pichini S, Martin I et al. Are false positive phencyclidine immunoas-say instant-view multi test results caused by overdose concentrations of ibuprofen, metamizol and dextromethorphan?. Ther Drug Monit 2007; 29: 671-673.
120. Warner A. Interference of household chemicals in immunoassay methods for drugs of abuse. Clin Chem 1989; 35: 648-651.
121. Wu AH, Forte E, Casella G, Sun K et al. CEDIA for screening drugs of abuse in urine and effect of adulterants. J Forensic Sci 1995; 40: 614-618.
122. Kim HU, Cerceo E. Interference by NaCl with the EMIT method of analysis for drugs of abuse. Clim Chem 1976; 22: 1936 [Letter to the Editor].
123. Uebel RA, Wium CA. Toxicological screening for drugs of abuse in samples adulterated with household chemicals. S Afr Med J 2002; 92: 547-549.
124. Schwarzhoff R, Cody JT. The effects of adulterating agents on FPIA analysis of urine for drugs of abuse. J Anal Toxicol 1993; 17: 14-17.
125. Baiker C, Serrano L, Lindner B. Hypochlorite adulteration of urine causing decreased concentration of delta-9-THC-COOH by GC/MS. J Anal Toxicol 1994; 18: 101-103.
126. Stolk LM, Scheijen JL. Urine adulteration with denture cleaning tablets [letter]. J Anal Toxicol 1997; 21: 403.
127. Pearson SD, Ash KO, Urry FM. Mechanism of false negative urine cannabinoid immunoassay screens by Visine eye drops. Clin Chem 1989; 35: 636-638.
128. Fogerson R, Schoendorfer D, Fay J, Spiehler V. Qualitative detection of opiates in sweat by EIAS and GC-MS. J Anal Toxicol 1997; 21: 451-458.
129. Rojsitthisak P, Wichitnithad W, Pipitharome O, Sanphanya K, Thanawattanawanich P. Simple HPLC determination of benzalkonium chloride in ophthalmic formulations containing antazoline and tetrahydrozoline. PDA J Pharm Sci Technol 2005; 59: 323-327.
130. Wu A, Bristol B, Sexton K, Cassella-McLane G, Holtman V, Hill DW. Adulteration of urine by urine luck. Clin Chem 1999; 45: 1051-1057.
131. Paul BD, Martin KK, Maguilo J, Smith ML. Effects of pyridinium chlorochromate adulterant (Urine Luck) on testing of drugs of abuse and a method for quantitative detection of chromium(VI) in urine. J Anal Toxicol 2000; 24: 233-237.
132. ElSohly MA, Feng S, Kopycki WJ, Murphy TP, Jones AB, Davis A, Carr D. A procedure to overcome interferences caused by adulterant "Klear" in the GC-MS analysis of 11-nor-A9-THC-9-COOH. J Anal Toxicol 1997; 20: 240-242 [Letter to the editor].
133. Tsai SC, ElSohly MA, Dubrovsky T, Twarowska B, Towt J, Salamone SJ. Determination of five abused drugs in nitrite-adulterated urine by immunoassay and gas chromatography-mass spectrometry. J Anal Toxicol 1998; 22: 474-480.
134. Tsai LS, ElSohly MA, Tsai SF, Murphy TO, Twarowska B, Salamone SJ. Investigation of nitrite adulteration on the immunoassay and GC-MS analysis of cannabinoids in urine specimens. J Anal Toxicol 2000; 24: 708-714.
135. Urry. F, Komaromy-Hiller G, Staley B, Crockett D, Kushnir M, Nelson G, Struempler R. Nitrite adulteration of workplace drug testing specimens: sources and associated concentrations of nitrite and distinction between natural sources and adulteration. J Anal Toxicol 1998; 22: 89-95.
136. George S, Braithwaite RA. The effect of glutaraldehyde adulteration of urine specimens on Syva EMIT II drugs of abuse assay. J Anal Toxicol 1996; 20: 195-196.
137. Wu AH, Forte E, Casella G, Sun K, Hemphill G, Forey R, Schanzenback H. CEDIA for screening drugs of abuse in urine and the effect of adulterants. J Forensci Sci 1995; 40: 614-618.
138. Goldberger BA, Caplan YH. Effect of glutaraldehyde (UrinAid) on detection of abused drugs in urine by immunoassay [Letter]. Clin Chem 1994; 40: 1605-1616.
139. Cody JT, Valtier S. Effects of Stealth adulteration on immunoassay testing for drugs of abuse. J Anal Toxicol 2001; 25: 466-470.
140. Cody JT, Valtier S, Kuhlman J. Analysis of morphine and codeine in samples adulterated with Stealth. J Anal Toxicol 2001; 25: 572-575.
141. 9-THC-9-carboxylic acid in urine. J Anal Toxicol 2002; 26: 460-463.
142. Burrows DL, Nicolaides A, Rice PJ, Duforc M, Johnson DA, Ferslew KE. Papain: a novel urine adulterant. J Anal Toxicol 2005; 29: 275-295.
143. Dasgupta A, Wahed A, Wells A. Rapid spot tests for detecting the presence of adulterants in urine specimens submitted for drug testing. Am J Clin Pathol 2002; 117: 325-329.
144. Freslew KE, Hagardorn AN, Roberts TA. Capillary ion electrophoresis of endogenous anions and anionic adulterants in human urine. J Forensic Sci 2001; 46: 615-626.
145. Ferslew KE, Nicolaides AN, Robert TA. Determination of chromate adulteration of human urine by automated colorimetric and capillary ion electrophoretic analyses. J Anal Toxicol 2003; 27: 36-39.
146. Paul BD. Six spectrometric methods for detection of oxidants in urine: implication in differentiation of normal and adulterated urine. J Anal Toxicol 2004; 28: 599-608.
147. Singh J, Elberlind JA, Hemphill DG, Holmstrom J. The measurement of nitrite in adulterated urine samples by high performance ion chromatography. J Anal Toxicol 1999; 23: 137-140.
148. Kinkennon AE, Black DL, Robert TA, Stout PR. Analysis of nitrite in adulterated urine samples by capillary electrophoresis. J Forensic Sci 2004; 49: 1094-1100.
149. Valtier S, Cody JT. A procedure for the detection of Stealth adulterant in urine samples. Clin Lab Sci 2002; 15: 111-115.
150. Wu A, Schmalz J, Bennett W Identification of Urin-Aid adulterated urine specimens by fluorometric analysis [Letter]. Clin Chem 1994; 40: 845-846.
151. King EJ. Performance of AdultaCheck 4 test strips for the detection of adulteration at the point of collection of urine specimen used for drugs of abuse testing. J Anal Toxicol 1999; 72 [Letter to the editor].
152. Peace MR, Tarnai LD. Performance evaluation of three on-site adulteration detection devices for urine specimens. J Anal Toxicol 2002; 26: 464-470.
153. King EJ. Performance of AdultaCheck 4 test stripes for the detection of adulteration at the point of collection of urine specimens used for drugs of abuse testing. J Anal Toxicol 1999; 23: 72.
154. Dasgupta A, Chughtai O, Hannah C, Davis B, Wells A. Comparison of spot tests with AdultaCheck 6 and Intect 7 urine test strips for detecting the presence of adulterants in urine specimens. Clin Chem Acta 2004; 34: 19-25.
155. Jones JT, Esposito FM. An assay evaluation of the methylene blue method for the detection of anionic surfactants in urine. J Anal Toxicol 2000; 24: 323-327.
156. MRO Case Studies (Health and Human Services of the US Government) 2005: (http://workplace.samhsa.gov/DrugTesting/Files-Drug-Testing/MROs/MRO%20Case%20 Studies%20-%20Ferbruary%202005.pdf)
157. Boorman M, Owens K. The Victorian legislative framework for the random testing drivers at the roadside for the presence of illicit drugs: an evaluation of the characteristics of drivers detected from 2004 to 2006. Traffic Inj Prev 2009; 10: 16-22.
158. Drummer OH, Gerostamoulos D, Chu M, Swann P et al. Drugs in oral fluid in randomly selected drivers. Forensic Sci Int 2007; 170: 105-110.
159. Boumba VA, Ziavrou KS, Vougioulakis T. Hair analysis as a biological indicator of drug use, drug abuse or chronic exposure ti environmental toxins. Int J Toxicol 2006; 25: 143-163.
160. Baumgartner AM, Jones PF, Baumgartner WA, Black CT. Radioimmunoassay of hair for determining opiate-abuse histories. J Nucl Med 1979; 20: 748-752.
161. Kintz P. Value of hair analysis in postmortem toxicology. Forensic Sci Int 2004; 142: 127-134.
162. Kronstrand R, Ahlner J, Dizdar N, Larson G. Quantitative analysis of desmethylselegiline, methamphetamine, and amphetamine in hair and plasma from Parkinson patients on long-term selegiline medication. J Anal Toxicol 2003; 27: 135-141.
163. Goldberger BA, Darraj AG, Caplan YH, Cone EJ. Detection of methadone, methadone metabolites, and other illicit drugs of abuse in hair of methadone-treatment subjects. J Anal Toxicol 1998; 22: 526-530.
164. Schaffer M, Hill V, Cairns T. Hair analysis for cocaine: the requirement for effective wash procedures and effects of drug concentration and hair porosity in contamination and decontamination. J Anal Toxicol 2005; 29: 319-326.
165. Hoffman BH. Analysis of race effects on drug-test results. J Occup Environ Med 1999; 41: 612-614.
166. Joya X, Papaseit E, Civit E, Pellegrini M et al. Unsuspected exposure to cocaine in preschool children from a Mediterranean city detected by hair analysis. Ther Drug Monit 2009 [E-pub ahead of print].
167. Garcia-Bournissen F, Nesterenko M, Karasjov T, Koren G. Passive environmental exposure to cocaine in Canadian children. Paediatr Drugs 2009; 11: 30-32.
168. Koren G, Klein J, Forman R, Graham K. Hair analysis of cocaine: differentiation between systemic exposure and external contamination. J Clin Pharmacol 1992; 32: 671-675.
169. Romano G, Barbera N, Lombardo I. Hair testing for drugs of abuse: evaluation of external cocaine contamination and risk of false positives. Forensic Sci Int 2001; 123: 119-129.
170. Paulsen RB, Wilkins DG, Slawson MH, Shaw K, Rollins DE. Effect of four laboratory decontamination procedures on the quantitative determination of cocaine and metabolites in hair by HPLC-MS. J Anal Toxicol 2001; 25: 490-496.
171. Cirimele V, Kintz P, Jamey C, Ludes B. Are cannabinoids detected in hair after washing with Cannabio shampoo?. J Anal Toxicol 1999; 23: 349-351.
172. Uhl M, Sachs H. Cannabinoids in hair: strategy to prove marijuana/hashish consumption. Forensic Sci Int 2004; 145: 143-147.
173. Rohrich J, Zorntlein S, Potsch L, Skopp G, Becker J. Effect of the shampoo Ultra Clean on drug concentrations in human hair. Int J Legal Med 2000; 113: 102-106.
174. Walsh JM, Flegel R, Crouch DJ, Cangianelli L, Baudys J. An evaluation of rapid point-of-collection oral fluid drug-testing devices. J Anal Toxicol 2003; 27: 429-439.
175. Walsh JM, Crouch DJ, Danaceau JP, Cangianelli L, Liddicoat L, Adkins R. Evaluation of ten oral fluid point-of-collection drug-testing devices. J Anal Toxicol 2007; 31: 44-54.
176. Ventura M, Pichini S, Ventura R, Leal S et al. Stability of drugs of abuse in oral fluid collection devices with purpose of external quality assessment schemes. Ther Drug Monit 2009; 31: 277-280.
177. Kintz P, Brunet B, Muller JF, Serra W et al. Evaluation of the Cozart DDVS test for cannabis in oral fluid. Ther Drug Monit 2009; 31: 131-134.
178. Kala V, Harris SE, Freijo TD, Gerlich S. Validation of analysis of amphetamine, opiates, phen-cyclidine, cocaine, benzoylecgonine in oral fluids by liquid chromatography-tandem mass spectrometry. J Anal Toxicol 2008; 32: 605-611.
179. Kaufman E, Lamster IB. The diagnostic applications of oral fluid-a review. Crit Rev Oral Biol Med 2002; 13: 197-212.
180. Wong RC, Tran M, Tung JK. Oral fluid drug tests: effects of adulterants and foodstuffs. Forensic Sci Int 2005; 150: 175-180.
181. Cooper G, Wilson L, Reid C, Baldwin D, Hand C, Spiehler V. Validation of the Cozart microplate EIA for analysis of opiates in oral fluid. Forensic Sci Int 2005; 154: 240-246.
182. Saito T, Wtsadik A, Scheidweiler KB, Fortner N, Takeichi S, Huestis MA. Validated gas chromatographic-negative ion chemical ionization mass spectrometric method for delta(9)-tetrahydrocannabinol in sweat patches. Clin Chem 2004; 50: 2083-2090.
183. Kacinko SL, Barnes AJ, Schwilke EW, Cone EJ, Moolchan ET, Huestis MA. Disposition of cocaine and its metabolites in human sweat after controlled cocaine administration. Clin Chem 2005; 51: 2085-2094.
184. Fogerson R, Schoendorfer D, Fay J, Spiehler V. Qualitative detection of opiates in sweat by EIA and GC-MS. J Anal Toxicol 1997; 21: 451-458.
185. Schmidt J, Boettcher C, Kuhnt C, Zenk MH. Poppy alkaloid profiling by electrospray tandem mass spectrometry and electrospray FT-ICR mass spectrometry after [ring-13C]-tyramine feeding. Phytochemistry 2007; 68: 189-202.
186. Reid RG, Durham DG, Boyle SP, Low AS, Wangboonskul J. Differentiation of opium and poppy straw using capillary electrophoresis and pattern recognition techniques. Anal Chim Acta 2007; 605: 20-27.
187. Pelders M, Ross JJ. Poppy seeds: difference in morphine and codeine content and variation in inter-and intra individual excretion. J Forensic Sci 1996; 41: 209-212.
188. Hill V, Cairns T, Cheng CC, Schaffewr M. Multiple aspects of hair analysis for opiates: methodology, clinical and workplace population, codeine and poppy seed ingestion. J Anal Toxicol 2005; 29: 696-703.
189. Thevis M, Opfermann G, Schanzer W. Urinary concentrations of morphine and codeine after consumption of poppy seeds. J Anal Toxicol 2003; 27: 53-56.
190. Keskin O, Sekerel BE. Poppy seed allergy: a case report and review of literature. Allergy Asthma Proc 2006; 27: 396-398.
191. Panasoff J. Poppy seed anaphylaxis. J Investig Allergol Clin Immunol 2008; 18: 224-225.
192. Unnithan S, Strang J. Poppy tea dependance. Br J Psychiatry 1993; 163: 813-814.
193. Sttentoff A, Kaa E, Worm K. Fatal intoxication in Denmark following intake of morphine from opium poppies. Z Rechtsmed 1988; 101: 197-204.
194. King M, McDonough MA, Drummer OH, Berkovic SF. Poppy tea and the baker's first seizure. Lancet 1997; 350: 716.
195. Van Thuyne W, Van Eenoo P, Delbeke FT. Urinary concentrations of morphine after the administration of herbal tea containing Papaveris fructus in relation to doping analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 785: 245-251.
196. Fraser AD, Worth D. Experience with a urine opiate screening and confirmation cutoff of 2000 ng/mL. J Anal Toxicol 1999; 23: 549-551.
197. Fritschi G, Prescott WR. Morphine levels in urine subsequent to poppy seed consumption. Forensic Sci Int 1985; 27: 111-117.
198. Struempler RE. Excretion of codeine and morphine following ingestion of poppy seeds. J Anal Toxicol 1987; 11: 97-99.
199. Hayes LW, Krassolt WG, Mueggier PA. Concentrations of morphine and codeine in serum and urine after ingestion of poppy seeds. Clin Chem 1987; 33: 806-808.
200. Meadway C, George S, Braithwaite R. Opiate concentrations following the ingestion of poppy seeds products-evidence for poppy seed defense. J Forensic Sci 1998; 96: 29-38.
201. Sproll C, Perz RC, Lachenmeier DW. Optimized LC/MS analysis of morphine and codeine in poppy seed and evaluation of their fate during food processing as a basis of risk analysis. J Agric Food Chem 2006; 54: 5292-5298.
202. Lo DS, Chan TH. Poppy seeds: implications of consumption. Med Sci Law 1992; 32: 296-302.
203. Moeller MR, Hammer K, Engel O. Poppy seed consumption and toxicological analysis of blood and urine samples. Forensic Sci Int 2004; 143: 183-186.
204. Trafkowski J, Madea B, Musshoff F. The significance of putative urinary markers of illicit heroin use after consumption of poppy seed products. Ther Drug Monit 2006; 28: 552-558.
205. Rohrig TP, Moore C. The determination of morphine in urine and oral fluid following ingestion of poppy seeds. J Anal Toxicol 2003; 27: 449-452.
206. Meneely KD. Poppy seed ingestion: the Oregon experience. J Forensic Sci 1992; 37: 1158-1162.
207. Liu HC, Ho HO, Liu RH, Yeh GC, Lin DL. Urinary excretion of morphine and codeine following the administration of single and multiple doses of opium preparations prescribed in Taiwan as "brown mixture." J Anal Toxicol 2006; 30: 225-231.
208. von Euler M, Villen T, Svensson JO, Stahle L. Interpretation of the presence of 6-monoacetylmorphine in the absence of morphine-3-glucuronide in urine samples: evidence of heroin abuse. Ther Drug Monit 2003; 25: 645-648.
209. Cone EJ, Clarke J, Tsanaclis L. Prevalance and disposition of drugs of abuse and opioid treatment drugs in oral fluid. J Anal Toxicol 2007; 31: 424-433.
210. Al-Amri AM, Smith RM, El-Haj BM, Juma's MH. The GC-MS detection and characterization of reticuline as a marker for opium use. Forensic Sci Int 2004; 142: 61-69.
211. Cassella G, Wu AH, Shaw BR, Hill DW. The analysis of thebaine in urine for the detection of poppy seed consumption. J Anal Toxicol 1997; 21: 376-383.
212. Westin AA, Slordal L. Passive inhalation of cannabis smoke-is it detectable?. Tidsskr Nor Laegeforen 2009; 129: 109-113.
213. Niedbala RS, Kardos KW, Fritch D, Kunsman K, Blum KA, Newland GA et al. Passive cannabis smoke exposure and oral fluid testing II. Two studies of extreme cannabis smoke exposure in a motor vehicle. J Anal Toxicol 2005; 29: 607-615.
214. Holler JM, Bosy TZ, Dunkley CS, Levine B et al. Delta-9- tetrahydrocannabinol content of commercially available hemp products. J Anal Toxicol 2008; 32: 428-432.
215. Costantino A, Schwartz RH, Kaplan P. Hemp oil ingestion causes positive urine tests for delta-9-tetrahydrocannabinol carboxylic acid. J Anal Toxicol 1997; 21: 482-485.
216. Struempler RE, Nelson G, Urry TM. A positive cannabinoid workplace drug test following the ingestion of hemp seed oil. J Anal Toxicol 1997; 21: 283-285.
217. Lehman T, Sager F, Brenneisen R. Excretion of cannabinoids in urine after ingestion of cannabis seed oil. J Anal Toxicol 1997; 5: 373-375.
218. Meier H, Vonesch HJ. Cannabis poisoning after eating salad. Schweiz Med Wochenschr 1997; 127: 214-218.
219. Leson G, Pless P, Grotenhermen F, Kalant H, ElSohly MA. Evaluating the impact of hemp food consumption on workplace drug tests. J Anal Toxicol 2001; 25: 691-698.
220. MROCase Studies (Health and Human Services of the US Government) 2005: (http://workplace.samhsa.gov/DrugTesting/Files-Drug-Testing/MROs/ MRO%20Case%20Studies% 20%20Ferbruary%202005.pdf)
221. Miech RA, Chilcoat H, Harder VS. The increase in the association of education and cocaine use over the 1980s and 1990s: evidence for a historical period effect. Drug Alcohol Depend 2005; 79: 311-320.
222. Shearer J, Johnston J, Fry CL, Kaye S et al. Contemporary cocaine use patterns and associated harms in Melbourne and Sydney, Australia. Drug Alcohol Rev 2007; 26: 537-543.
223. Fairley HB. Anesthesia in the Inca empire. Rev Esp Anestesiol Reanim 2007; 54: 556-562.
224. Evo Morales Ayma, The President of Bolivia; New York Times opinion editorial, March 14, 2009.
225. http://en.wikipedia.org/wiki/Coca-tea Accessed 3/12/2009.
226. Galarza-Guzman M, Penaloza-Imana R, Afcha L, Aguilar Valerio M et al. Effect of coca chewing on the glucose tolerance test. Medicine (B Aries) 1997; 57: 261-264.
227. Favier R, Caceres E, Guillon L, Sempore B et al. Coca chewing for exercise: hormonal and metabolic responses of non habitual chewers. J Appl Physiol 1996; 81: 1901-1907.
228. Weil AT. Coca leaf as a therapeutic agent. Am J Drug Alcohol Abuse 1987; 5: 75-86.
229. Weil AT. The therapeutic value of coca in contemporary medicine. J Ethnopharmacol 1981; 3: 367-376.
230. Jenkins AJ, Llosa T, Montoya I, Cone EJ. Identification and quantitation of alkaloids in coca tea. Forensic Sci Int 1996; 77: 179-189.
231. Jackson GF, Saady JJ, Poklis A. Urinary excretion of benzoylecgonine following ingestion of health Inca tea. Forensic Sci Int 1991; 49: 57-64.
232. Mazor SS, Mycyk MB, Wills BK, Brace LD, Gussow L, Erickson T. Coca tea consumption causes positive urine cocaine assay. Eur J Emerg Med 2006; 13: 340-341.
233. Turner M, McCrory P. Time for tea anyone? Johnston A. Br J Sports Med 2005; 39: e37.
234. The Florida Times Union; Story by Timothy J. Gibbons; January 10, 2009; http://www.tullylegal.com, accessed 3/13/2009.
235. Garrido vs Cook County Sheriff's Merit Board, June 9, 2004, State of Illinois No-1-03-1128.
236. Hickey K, Seliem R, Shields J, McKee A et al. A positive drug test in the pain management patient: deception or herbal cross-reactivity?. Clin Chem 2002; 48: 958-960.
237. Downham TF 2nd, Cawley RA, Salley SO, Dal Santo G. Systematic toxic reaction to procaine penicillin G. Sex Transm Dis 1978; 5: 4-9.
238. Alteri M, Bogema S, Schwartz RH. TAC topical anesthesia produces positive urine test for cocaine. Ann Emerg Med 1990; 19: 577-579.
239. McKinney CD, Postiglione KF, Herold DA. Benzocaine adulterated street cocaine in association with methemoglobinemia. Clin Chem 1992; 38: 596-597.
240. Arufe-Martinez MI, Romero-Palanco JL. Identification of cocaine-lidocaine mixtures (rock cocaine) and other illicit cocaine preparations using derivative absorption spectroscopy. J Anal Toxicol 1988; 12: 192-196.
241. Oyler J, Darwin WD, Cone EJ. Cocaine contamination of United States paper currency. J Anal Toxicol 1996; 20: 213-216.
242. Negrusz A, Perry JL, Moore C. Detection of cocaine on various denominations of United States currency. J Forensic Sci 1998; 43: 626-629.
243. Jenkins AJ. Drug contamination in US paper currency. Forensic Sci Int 2001; 121: 189-193.
244. Zuo Y, Zhang K, Wu J, Rego C et al. An accurate and nondestructive GC method for determination of cocaine on US paper currency. J Sep Sci 2008; 31: 2440-2450.
245. Lavins ES, Lavins BD, Jenkins AJ. Cannabis (marijuana) contamination of United States and foreign paper currency. THC in J Anal Toxicol 2004; 28: 439-442.
246. Hudson JC. Analyses of currency of cocaine contamination. J Can Soc Forensic Sci 1989; 22: 203-219.
247. Baselt RC, Chang JY, Yoshikawa DM. On the dermal absorption of cocaine. J Anal Toxicol 1990; 14: 383-384.
248. ElSohly MA. Urinalysis and casual handling of marijuana and cocaine. J Anal Toxicol 1991; 14: 46.
249. Cone EJ, Yousefnejad D, Hillsgrove MJ, Holicky B et al. Passive inhalation of cocaine. J Anal Toxicol 1995; 19: 399-411.
250. Le SD, Taylor RW, Vidal D, Lovas JJ et al. Occupational exposure to cocaine involving crime lab personnel. J Forensic Sci 1992; 37: 959-968.
251. Gehlhausen JM, Klette KL, Stout PR, Given J. Occupational cocaine exposure of a crime laboratory personnel preparing training aids for a military working dog program. J Anal Toxicol 2003; 27: 453-458.
252. MRO Case Studies (Health and Human Services of the US Government) 2005: (http://workplace.samhsa.gov/DrugTesting/Files-Drug-Testing/MROs/ MRO%20Case%20Studies% 20-%20Ferbruary%202005.pdf)
253. Zapata LB, Hills SD, Marchbanks PA, Curtis KM et al. Methamphetamine use is independently associated with risky sexual behavior and adolescent pregnancy. J Sch Health 2008; 78: 641-658.
254. Redback CJ, Shoptaw S, Grella CE. Methamphetamine use trends among street recruited gay and bisexual males from 1999 to 2007. J Urbal Health 2008; 85: 874-879.
255. Pedersen W, Skrondal A. Ecstasy and new patterns of drug use: a normal population study. Addiction 1999; 94: 1695-1706.
256. Moore KA. Amphetamines/sympathomimetic amines. In: B Levine ed. Principles of Forensic Toxicology. AACC Press, Washington, D.C, 2003, pp. 341-348.
257. Grinstead GF. Ranitidine and high concentrations of phenylpropanolamine cross react in the EMIT monoclonal amphetamine/methamphetamine assay. Clin Chem 1989; 35: 1998-1999.
258. Poklis A. Unavailability of drug metabolite reference material to evaluate false-positive results for monoclonal EMIT-d.a.u. assay of amphetamine. Clin Chem 1992; 38: 2580.
259. Caplan YH, Levine B, Goldberger B. Fluorescence polarization immunoassay evaluated for screening for amphetamine and methamphetamine in urine. Clin Chem 1987; 33: 1200-1202.
260. Papa P, Rocchi L, Mainardi C, Donzelli G. Buflomedil interference with the monoclonal EMIT d.a.u. amphetamine/methamphetamine immunoassay. Eur J Clin Chem Clin Biochem 1997; 35: 369-370.
261. Olsen KM, Gulliksen M, Christophersen AS. Metabolites of chlorpromazine and brompheniramine may cause false-positive urine amphetamine results with monoclonal EMIT d.a.u. immunoassay. Clin Chem 1992; 38: 611-612.
262. Smith-Kielland A, Olsen KM, Christophersen AS. False-positive results with EMIT II amphetamine/methamphetamine assay in users of common psychotropic drugs. Clin Chem 1995; 41: 951-952.
263. Dasgupta A, Saldana S, Kinnaman G, Smith M, Johansen K. Analytical performance evaluation of EMIT II monoclonal amphetamine/methamphetamine assay: more specificity than EMIT d.a.u. monoclonal amphetamine/methamphetamine assay. Clin Chem 1993; 39: 104-108.
264. Joseph R, Dickerson S, Willis R, Frankenfield D, Cone EJ, Smith DR. Interference by nonsteroidal anti-inflammatory drugs in EMIT and TDx assays for drugs of abuse. J Anal Toxicol 1995; 19: 13-17.
265. Nice A, Maturen A. False-positive urine amphetamine screen with ritodrine. Clin Chem 1989; 35: 1542-1543.
266. Jones R, Klette K, Kuhlman JJ, Levine B, Smith ML, Watson CV, Selavka CM. Trimethobenzamide cross-reacts in immunoassays of amphetamine-methamphetamine. Clin Chem 1993; 39: 699-700.
267. Kozer E, Verjee Z, Koren G. Misdiagnosis of a mexiletine overdose because of a nonspecific result of urinary toxicology screening. New Eng J Med 2000; 343(26): 1971.
268. Schmolke M, Hallbach J, Guder WG False-positive results for urine amphetamine and opiate immunoassays in a patient intoxicated with perazine. Clin Chem 1996; 42: 1725-1726.
269. Takayasu T, Ohshima T, Nishigami J, Kondo T et al. Screening and determination of methamphetamine and amphetamine in the blood, urine and stomach contents in emergency medical care and autopsy cases. J Clin Forensic Med 1995; 2: 25-33.
270. Shindelman J, Mahal J, Hemphill G, Pizzo P, Coty WA. Development and evaluation of an improved method for screening of amphetamines. J Anal Toxicol 1999; 23: 506-510.
271. Woodworth A, Saunders AN, Koenig JW, Moyer TP, Turk J, Dietzen DJ. Differentiation of amphetamine/methamphetamine and other cross-immunoreactive sympathomimetic amines in urine samples by serial dilution testing. Clin Chem 2006; 52: 743-746.
272. Melanson SE, Lee-Lewandrowski E, Griggs DA, Long WH et al. Reduced interference by phenothiazine in amphetamine drug of abuse immunoassay. Arch Pathol Lab Med 2006; 130: 1834-1838.
273. Cooke BJ. Chirality of methamphetamine and amphetamine from workplace urine samples. J Anal Toxicol 1994; 18: 49-51.
274. Poklis A, Jortani SA, Brown CS, Crooks CR. Response of the EMIT II amphetamine/methamphetamine assay to specimens collected following use of Vicks® inhalers. J Anal Toxicol 1993; 17: 284-286.
275. Poklis A, Moore KA. Stereoselectivity of TDxADx/FLx amphetamine/ methamphetamine II immunoassay-response of urine specimens following nasal inhaler use. J Toxicol Clin Toxicol 1995; 33: 35-41.
276. MRO Case Studies (Health and Human Services of the US Government) 2005: http://workplace.samhsa.gov/DrugTesting/Files-Drug-Testing/MROs/ MRO%20Case%20Studies% 20-%20Ferbruary%202005.pdf
277. Haller CA, Benowitz NL. Adverse and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Eng J Med 2000; 343: 1833-1838.
278. Nguyen MH, Ormiston T, Kurani S, Woo DK. Amphetamine lacing of an Internet marketed nutraceutical. Mayo Clinic Proc 2006; 81: 1627-1629.
279. Haaz S, Fontaine KB, Cutter G, Limdi N et al. Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update. Obes Res 2006; 7: 79-88.
280. Nguyen DT, Bui LT, Ambrose PJ. Response of CEDIA amphetamines assay after a single dose of bitter orange. Ther Drug Monit 2006; 28: 252-254.
281. Hornbeck CL, Carrig JE, Czarny RJ. Detection of a GC/MS artifact peak as metham-phetamine. J Anal Toxicol 1993; 17: 257-263.
282. ElSohly MA, Stanford DF, Sherman D, Shah H, Bernot D, Turner CE. A procedure for eliminating interferences from ephedrine and related compounds in the GC/MS analysis of amphetamine and methamphetamine. J Anal Toxicol 1992; 16: 109-111.
283. Dasgupta A, Gardner C. Distinguishing amphetamine and methamphetamine from other interfering sympathomimetic amines after various fluoro derivatization and analysis by gas chromatography-chemical ionization mass spectrometry. J Forensic Sci 1995; 40: 1077-1081.
284. Elliott S, Burgers V. Investigative implications of instability and metabolism of mebeverine. J Anal Toxicol 2006; 30: 91-97.
285. Kraemer T, Wenning R, Maurer HH. The antispasmodic drug mebeverine leads to positive amphetamine results by fluorescence polarization immunoassay (FPIA)-studies on the toxicological analysis of urine by FPIA and GC-MS. J Anal Toxicol 2001; 25: 333-338.
286. Musshoff F. Illegal or legitimate use? Precursor compounds to amphetamine and metham-phetamine. Drug Metab Rev 2000; 32: 15-44.
287. Cody JT, Valtier S, Nelson SL. Amphetamine enantiomer excretion profile following administration of Adderall. J Anal Toxicol 2003; 27: 485-492.
288. Cody JT, Valtier S. Detection of amphetamine and methamphetamine following administration of benzphetamine. J Anal Toxicol 1998; 22: 299-309.
289. Kraemer T, Roditis SK, Peters FT, Maurer HH. Amphetamine concentrations in human urine following single-dose administration of calcium antagonist prenylamine-studies using fluorescence polarization immunoassay (FPIA) and GC-MS. J Anal Toxicol 2003; 27: 68-73.
290. Maurer HH, Kraemer T. Toxicological detection of selegiline and its metabolites in urine using fluorescence polarization immunoassay (FPIA) and gas chromatography-mass spectrometry (GC-MS) and differentiation by enantioselective GC-MS of the intake of selegiline from abuse of methamphetamine or amphetamine. Arch Toxicol 1992; 66: 675-678.
291. MRO Case Studies (Health and Human Services of the US Government) 2005: http://work-place.samhsa.gov/DrugTesting/Files-Drug-Testing/MROs/ MRO%20Case%20Studies%20-%20Ferbruary%202005.pdf
292. Moore KA. Amphetamines/sympathomimetic amines. In: Levine B ed. Principles of Forensic Toxicology, Revised and Updated. 2nd ed. AACC Press, Washington, DC, 2006, 277-296.
293. Manchikanti L. National drug control policy and prescription drug abuse: facts and fallacies. Pain Physician 2007; 10: 399-424.
294. Manchikanti L, Singh A. Therapeutic opioids: a ten year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 2008; 11(2 Suppl): S63-S88.
295. Wunsch MJ, Nakamoto K, Behonick G, Massello W. Opioid deaths in rural Virginia: a description of the high prevalence of accidental fatalities involving prescribed medications. Am J Addict 2009; 18: 5-14.
296. DeRienz RT, Holler JM, Manos ME, Jemionek J et al. Evaluation of four immunoassays screening kits for the detection of benzodiazepines in urine. J Anal Toxicol 2008; 32: 433-437.
297. Klette KL, Wiegand RF, Horn CK, Stout PR et al. Urine benzodiazepine screening using Roche Online KIMS immunoassay with beta-glucuronidase hydrolysis and confirmation by gas chromatography-mass spectrometry. J Anal Toxicol 2005; 19: 193-200.
298. Fraser AD, Jowell P. Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine. J Anal Toxicol 1998; 22: 50-54.
299. Piergies AA, Sainati S, Roth-Schechter B. Lack of cross-reactivity of Ambien (zolpidem) with drugs in standard urine drug screens. Arch Pathol Lab med 1997; 121: 392-394.
300. ElSohly MA, Gul W, Murphy TP, Avula B. LC-(TOF) MS analysis of benzodiazepines in urine from alleged victims of drug facilitated sexual assault. J Anal Toxicol 2007; 31: 505-514.
301. ElSohly MA, Gul W, Avula B, Murphy TP et al. Simultaneous analysis of thirty five benzodi-azepines using liquid chromatography-mass spectrometry time of flight. J Anal Toxicol 2008; 32: 547-561.
302. Reisfield GM, Haddad J, Wilson GR, Johannsen LM et al. Failure of amoxicillin to produce false-positive urine screens for cocaine metabolite. J Anal Toxicol 2008; 32: 315-318.
303. Bruns AD, Zeiske LA, Jacobs AJ. Analysis of the cocaine metabolite in the urine of patients and physicians during clinical use. Otolaryngol Head Neck Surg 1994; 111: 722-726.
304. Kavanagh KT, Maijub AG, Brown JR. Passive exposure to cocaine in medical personnel and its effect on urine drug screening test. Otolaryngol Head Neck Surg 1992; 107: 363-366.
305. Jacobson DM, Berg R, Grinstead GF, Kruse JR. Duration of positive urine for cocaine metabolite after ophthalmic administration: implications for testing patients with suspected Horner syndrome using ophthalmic cocaine. Am J Ophthalmol 2001; 131: 742-747.
306. Patrinely JR, Cruz OA, Reyna GS, King JW. The use of cocaine as an anesthetic in lacrimal surgery. J Anal Toxicol 1994; 18: 54-56.
307. Altieri M, Bogema S, Schwartz RH. TAC topical anesthesia produces positive urine test for cocaine. Ann Emerg Med 1990; 19: 577-579.
308. Smith ML, Hughes RO, Levine B, Dickerson S et al. Forensic drug testing for opiates. VI. Urine testing for hydromorphone, hydrocodone, oxymorphone and oxycodone with commercial opiate immunoassays and gas chromatography-mass spectrometry. J Anal Toxicol 1995; 19: 18-26.
309. Dunn KE, Sigmon SC, McGee MR, Heil MR et al. Evaluation of ongoing oxycodone abuse among methadone maintained patients. J Subst Abuse Test 2008; 35: 451-456.
310. Popa C, Beck O, Brodin K. Morphine formation from ethylmorphine: implications for drugs of abuse testing in urine. J Anal Toxicol 1998; 22: 142-147.
311. Wasam AD, Michna E, Janfaza D, Greenfield S et al. Interpreting urine drug tests: prevalence of morphine metabolism to hydromorphone in chronic pain patients treated with morphine. Pain Med 2008; 9: 918-923.
312. Cone EJ, Caplan YH, Moser F, Robert T et al. Evidence that morphine is metabolized to hydromorphone but not to oxymorphone. J Anal Toxicol 2008; 32(4): 319-323.
313. Oyler JM, Cone EJ, Joseph RE Jr, Huestis MA. Identification of hydrocodone in human urine following controlled codeine administration. J Anal Toxicol 2000; 24: 530-535.
314. Murao S, Manabe H, Yamashita T, Sekikawa T. Intoxication with over the counter antitussive medication containing dihydrocodeine and chlorpheniramine causes generalized convulsion and mixed acidosis. Intern Med 2008; 47: 1013-1015.
315. Coffman KL. The debate about marijuana usage in transplant candidates: recent medical evidence on marijuana health effects. Curr Opin Organ Transplant 2008; 13: 189-195.
316. Rossi S, Yash T, Bentley H, van der Brande G et al. Characterization of interference with six commercial d9-tetrahydrocannabinol immunoassays by efavirenz glucuronide in urine. Clin Chem 2006; 52: 896-897 [letter to the Editor].
317. ElSohly MA, deWit H, Wachtel SR, Feng S et al. Delta 9- tetrahydrocannabivarin as a marker for ingestion of marijuana versus Marinol: results of a clinical study. J Anal Toxicol 2001; 25: 565-571.
318. di Tomaso E, Beltramo M, Piomelli D. Brain cannabinoids in chocolate. Nature 1996; 382(6593): 677-678.
319. James JS. Marijuana and chocolate. AIDS Treat News 1996; 18(2567): 3-4.
320. Tytgat J, Van Boven M, Daenens P. Cannabinoid mimics in chocolate utilized as an argument in court. Int J Legal Med 2000; 113: 137-139.